阿伐斯汀 T4551

Product Introduction
Bioactivity


英文名: Acrivastine

描述: Acrivastine (Acrivastin) 是一种短效组胺 1 受体拮抗剂，可用于研究过敏性鼻炎。

体内活性: Acrivastine (usually 8mg three times daily) is an effective and well-tolerated antihistamine in the treatment of chronic urticaria and allergic rhinitis. Acrivastine causes less drowsiness than clemastine, the incidence of adverse effects being indistinguishable from that with placebo or terfenadine. In the treatment of dermatoses in which histamine has a pathogenetic role, the efficacy of acrivastine is superior to that of placebo and similar to that of usual dosages of clemastine, hydroxyzine, chlorpheniramine, cyproheptadine or terfenadine [1]. Both 4 mg and 8 mg acrivastine alleviate the symptoms of seasonal allergic rhinitis with significant improvements in the symptom scores for sneezing, running nose and the calculated overall score. In addition, 8 mg acrivastine reduces the symptom scores for watery eyes and itchy throat. Acrivastine is both well tolerated and effective in the treatment of seasonal allergic rhinitis [2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 5 mg/mL (14.35 mM)


关键字: Histamine Receptor | inhibit | Acrivastine | Inhibitor

相关产品: Psoralenoside | OXOMEMAZINE | Bepotastine Besilate | LML134 | Buclizine dihydrochloride | N-Acetylhistamine | Histamine Phosphate | Paliperidone | Histamine dihydrochloride | Betahistine dihydrochloride

相关库: Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Inhibitor Library | GPCR Compound Library | Anti-Cancer Approved Drug Library | Target-Focused Phenotypic Screening Library | Nonsteroidal Anti-Inflammatory Compound Library

阿伐斯汀 T4551信息由TargetMol中国为您提供，如您想了解更多关于阿伐斯汀 T4551报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途